Sorrento Therapeutics Raises $30M, Shifts To NASDAQ

San Diego-based Sorrento Therapeutics, a biopharmaceuticals firm focused on oncology, and therapeutic products for inflammation, metabolic, and infectious diseases, has raised $30M in a public offering, and has been listed on the NASDAQ Capital Market. The firm--which had formerly been OTC traded--said it raised approximately $30M by offering up 4,150,000 shares of its common stock at $7.25 per share. The firm is now trading as SRNE.